CubaMinrex. Sitio del Ministerio de Relaciones Exteriores de Cuba

Cuban Heberprot-P Proves Effectiveness in Treatment of Diabetic Foot Patients.

CUBA, February 28th, 2011.-  Heberprot-P, a leading medicament in the Cuban biotechnological and pharmaceutical industry, has proven its effectiveness and safety in the treatment of more than 22,000 patients suffering from diabetic foot ulcers.

The director of the Center for Genetic Engineering and Biotechnology (CIGB), Luis Herrera Martinez, affirmed that a clinical study in several European countries will contribute with new data on the product.

He recalled that it has been applied with excellent results in the quality of life of patients in Venezuela, Ecuador, Argentina, Uruguay, Algeria, Dominican Republic and Libya; aiming at its expansion towards Russia, China, and South Africa.

Herrera noted that pharmacosurveillance studies confirm that Heberprot-P is safe to use in the treatment of deep ulcers in lower limbs with almost no relapses, second injuries or amputations for this cause.

He explained that CIGB is carrying out researches addressed to improving treatments with this medicament, the only one of the kind in the world, and it aims at developing a new clinical study in ulcers with high levels of ischemia, to continue expanding its use.

According to some data offered by the World Health Organization (WHO), nearly 450 million people are expected to suffer from diabetes for 2025, and it is likely that 15-35 per cent of these people will suffer from a diabetic foot ulcer.

That’s why, it is so important to spread the use of this Cuban therapeutic alternative, patented in 2006, which stimulates the formation of useful tissue to close injuries, and reduces considerably the number of patients to go through amputation surgeries. (Cubaminrex- Cuban News Agency)